Chemoenzymatic modification of cell-surface glycan structures has emerged as a complementary approach to metabolic oligosaccharide engineering. Here, we identify Pasteurella multocida α2-3-sialyltransferase M144D mutant, Photobacterium damsela α2-6-sialyltransferase, and Helicobacter mustelae α1-2-fucosyltransferase, as efficient tools for live-cell glycan modification. Combining these enzymes with Helicobacter pylori α1-3-fucosyltransferase, we develop a host-cell-based assay to probe glycan-mediated influenza A virus (IAV) infection including wild-type and mutant strains of H1N1 and H3N2 subtypes. At high NeuAcα2-6-Gal levels, the IAV-induced host-cell death is positively correlated with haemagglutinin (HA) binding affinity to NeuAcα2-6-Gal. Remarkably, an increment of host-cell-surface sialyl Lewis X (sLe X ) exacerbates the killing by several wild-type IAV strains and a previously engineered mutant HK68-MTA. Structural alignment of HAs from HK68 and HK68-MTA suggests formation of a putative hydrogen bond between Trp222 of HA-HK68-MTA and the C-4 hydroxyl group of the α1-3-linked fucose of sLe X , which may account for the enhanced host cell killing of that mutant.
C omplementary to metabolic oligosaccharide engineering (MOE) 1 , chemoenzymatic glycan labeling and modification have emerged as valuable tools to modify glycan structures within a cellular environment [2] [3] [4] . Unlike MOE, which relies on a cell or an organisms's own glycan biosynthetic mechinary to incorporate unnatural monosaccharides with linkage promiscuity, chemoenzymatic glycan modification utilizes a recombinant glycosyltransferase to transfer natural or unnatural monosaccharides with novel functions from activated nucleotide sugars to glycoconjugates on the cell surface with linkage specificity. For these reasons, chemoenzymatic glycan modification provides a facile and more precise way for probing the function of glycans in cellular processes.
In their pioneering work, Sackstein, Xia et al., applied chemoenzymatic glycan modification based on human α1-3-fucosyltransferase (FT) to install α1-3-linked fucose (Fuc) onto the cell-surface, thereby creating E-selectin ligand, sLe X (NeuAcα2-3-Galβ1-4-(Fucα1-3)-GlcNAc), so as to enhance the engraftment and trafficking of human multipotent mesenchymal stromal cells and cord blood cells 5, 6 . In our previous work, we employed chemoenzymatic glycan modification to tune cell-surface receptor signaling and stem cell proliferation 2, 7 . Combining this method with bioorthogonal click chemistry, several labs, including our own, have demonstrated that imaging and profiling of specific cellular glycans can be realized [8] [9] [10] . Recently, we also applied this method to construct live cell-based glycan arrays on the surface of Chinese hamster ovary (CHO) Lec2 mutant cells possessing a relatively homogeneous repertoire of N-linked glycoforms 11 .
To date, glycosyltransferases from both mammalian organisms and bacteria have been used for chemoenzymatic glycan modification. Mammalian Golgi glycosyltransferases are type II transmembrane proteins 12 . For cell-surface glycan modification, truncated versions are often used, including human FT6 and FT7 and ST6Gal1, ST3Gal4, and ST3Gal1 2,5,9,13 . Bacterial glycosyltransferases, on the other hand, often lack the transmembrane domain and, therefore, are more easily expressed in Escherichia coli as soluble proteins. Notable examples include Helicobacter pylori α1-3-FT (Hp1,3FT), the bacterial homologue of the human blood group A antigen glycosyltransferase, and the Campylobacter jejuni β1-4-Nacetylgalactosaminyl transferase 10, 14, 15 . Unfortunately, many bacterial glycosyltransferases that are active for assembly of oligosaccharides in test tubes do not exhibit activities on the cell surface.
Here, to expand the enzyme repertoire for chemoenzymatic glycan modification, we perform a screen to identify bacterial glycosyltransferases with relaxed donor specificity that can be used for cell-surface glycan modification. We report that Pasteurella multocida α2-3-ST M144D mutant (Pm2,3ST-M144D), Photobacterium damsela α2-6-ST (Pd2,6ST), and H. mustelae α1-2-FT (Hm1,2FT) can be adopted as useful tools for this application (Fig. 1a) . Moreover, Pm2,3ST-M144D and Pd2,6ST are tolerant to large substituents introduced to the C-5 position of the cytidine-5′-monophosphate-N-acetylneuraminic acid (CMPNeuAc) donor. We successfully use these two STs to survey the expression patterns of their respective glycan acceptors in tissue specimens. Combining these enzymes with our previously discovered Hp1,3FT, we develop a live cell-based assay to analyze host-cell glycan-mediated influenza virus infection.
Results

Screening recombinant bacterial STs and FTs.
In the screening that we performed, natural and unnatural nucleotide sugars functionalized with biotin were used to assess if they can be accepted as the donor substrates of glycosyltransferases of interest. Initially, we focused our screen on sialyltransferases and fucosyltransferases due to the fact that sialic acid (Sia), Fuc, and galactose (Gal) are the three most common monosaccharides found on cell-surface glycans 16 . Sia α2-3-or α2-6-linked to terminal Gal, respectively, are exploited by avian and human influenza virus as receptors for host infection 17 . On the other hand, Fuc residues, when attached to terminal Gal in an α1-2-linkage or attached to the GlcNAc of N-acetyllactosamine in an α1-3-linkage, form blood group H antigen and Lewis X (Le X , Galβ1-4-(Fucα1-3)-GlcNAc), respectively 16 . Unlike Hp1,3FT, which has been used extensively for glycan modification, no other bacterial STs or FTs have been exploited to transfer biophysical probes (e.g., biotin and fluorescent dyes) directly onto cell surfaces for such an application.
We employed the CHO cell mutant Lec2 cells 18, 19 in this screen. Lec2 has a minimum level of sialylation, resulting in uncapped LacNAc and polyLacNAc on cell-surface N-glycans. After incubating with each individual of these enzymes/donor substrate pair, newly formed glycan epitopes of specific linkage were probed by fluorescently labeled lectins, including Ulex europaeus agglutinin 1 (UEA 1, specific for α1-2-linked Fuc), Aleuria aurantia lectin (AAL, specific for α1-3-and α1-6-linked Fuc), Maackia amurensis lectin (MAL, specific for α2-3-linked Sia, and Sambucus nigra lectin (SNA, specific for α2-6-linked Sia). Quantifying the cell-surface lectin staining signals, we discovered two sialyltransferases, Pm2,3ST-M144D 20 and Pd2,6ST [20] [21] [22] , and a fucosyltransferase, Hm1,2FT 23 , that can install natural sialic acid or fucose, respectively, onto the cell surface (Figs. 1f, g ). Consistent with our previous observations, robust AAL staining siganl was obtained when Lec2 cells were treated with Hp1,3 FT and guanosine 5'-diphospho-Fuc (GDP-Fuc). For enzymes providing positive signals, dose-dependent modification was observed. For example, as shown in Supplementary Fig. 2 , cellassociated ECA staining decreased while SNA staining increased along with increasing the concentration of the CMP-NeuAc for Pd2,6ST-mediated Lec2 cell sialylation.
To further validate the activities of Hm1,2FT, Hp1,3FT, Pm2,3ST-M144D, and Pd2,6ST, we performed in vitro glycosylation reactions using the natural donor substrates, CMP-NeuAc (for STs) and GDP-Fuc (for FTs), and type 2 N-acetyllactosamine (LacNAc, Galβ1-4-GlcNAc) as the acceptor. Thin-layer chromatography (TLC) and liquid chromatography-mass spectrometry (LC/MS) analysis confirmed the formation of Fucα1-2-Galβ1-4-GlcNAc, NeuAcα2-3-Galβ1-4-GlcNAc, NeuAcα2-6-Galβ1-4-GlcNAc, and Le X in Hm1,2FT, Pm2,3ST-M144D, Pd2,6ST, and Hp1,3FT-mediated transformations, respectively (Figs. 1b, c) . Consistent with a previous report 22 , when trimeric LacNAc was used as the acceptor substrate, both terminal and internal galactose residues were modified by Pd2,6ST.
Subsequently, Fucα1-2-Galβ1-4-GlcNAc was treated with Hp1,3FT or Pd2,6ST to produce Lewis Y or Fucα1-2-(NeuAcα2-6)-Galβ1-4-GlcNAc, respectively (Figs. 1c-e) . By treating Le X with Pm2,3ST-M144D and CMP-NeuAc, sLe X was produced (Fig. 1d) .
Evaluating the donor substrate promiscuity of STs and FTs. Originally reported by Chen and coworkers, Pm2,3ST-M144D and Pd2,6ST, are highly efficient for one-pot chemoenzymatic oligosaccharide synthesis 20, 24 . These enzymes have broad substrate scopes, tolerating functional groups including azide, alkyne, acetyl, O-methyl introduced at either the N-acyl side chain or the C-9 position. Likewise, Hm1,2FT has been used to synthsize the human blood H antigen. However, the donor substrate scope of this enzyme remains unexplored. To profile the tolerance of the above three enzymes for unnatural donor substrates to modify cell-surface glycans, we used azide-bearing sugar donors GDP-FucAz and CMP-SiaNAz. In this experiment, Lec2 cells were incubated with a sialyltransferase (Pm2,3ST-M144D or Pd2,6ST) and CMP-SiaNAz, or with a fucosyltransferase (Hp1,3FT or Hm1,2FT) and GDPFucAz. Following the enzymatic treatment, the modified cells were reacted with an alkynyl biotin via the ligand (BTTPS)-assisted copper-catalyzed azide-alkyne [3 + 2] cycloaddition reaction (CuAAC) 25 , and probed with Alexa Fluor 488-streptavidin. Flow cytometry analysis revealed that Pm2,3ST-M144D-or Pd2,6ST-treated Lec2 cells were robustly labeled, and the labeling was timedependent (Figs. 1h, i). As expected, Hp1,3FT-treated cells also exhibited significant labeling ( Supplementary Fig. 3A, B) . However, no signals were detectable for the Hm1,2FT-treated cells (Supplementary Fig. 3C ), suggesting that this enzyme is unable to accept the azide-functionalized donor. The non-tolerance of unnatural donors by Hm1,2FT was further confirmed by in vitro LacNAc modification ( Supplementary Fig. 3D, E) .
Further evaluation of the donor substrate scope of Pm2,3ST-M144D and Pd2,6ST revealed that besides the N-acyl modified CMP-SiaNAz, these two enzymes were capable of incorporating other CMP-Sia analogs, including CMP-9AzSia 26 , CMPSiaNAl 27 , and CMP-SiaNPoc 11 , onto cell-surface glycans (Supplementary Fig. 4) .
To survey if the promiscuity of Pm2,3ST-M144D and Pd2,6ST could enable the transfer of biotin-or Cy3-functionalized CMP-Sia derivatives directly to the cell surface for one-step glycan labeling, Lec2 cells were incubated with either enzyme in the presence of crude conjugation product of CMP-SiaNAz-Cy3 or CMP-SiaNAzbiotin. Biotinylated cells were further probed with Alexa Fluor 647-streptavidin. The cell-surface fluorescence of streptavidin-labeled or Cy3-labeled cells were then quantified by flow cytometry or examined by fluorescence microscopy, respectively. We detected strong fluorescent signal in both enzyme-treated cells. In control experiments, only background fluorescence was observed for cells treated with CMP-donors in the absence of both STs (Fig. 2a-d) . To confirm that these signals were produced from glycoprotein labeling, lysates of treated Lec2 cells, CHO cells and Lec8 cells were collected. Anti-biotin western blot confirmed that biotin was incorporated into glycoproteins of Lec2 cells and CHO cells (MW 55-250 KD), not the mutant CHO Lec8 cells that lack cell-surface LacNAc (Fig. 2f, g ). Moreover, PNGase F releasement of N-linked glycans essentially abolished all signal of labeled CHO and Lec2 cells, suggesting that LacNAc residues in N-linked glycans are the primary targets labeled by these enzymes. However, it is also possible that CHO cells express low levels of extended core 1 and core 2 O-glycans. Therefore, there are few acceptor substrates to be modified by ST(Pm2,3ST-M144D or Pd2,6ST).
STs-based chemoenzymatic labeling of tissue specimens. Next, we evaluated the feasibility of labeling tissue specimens via onestep ST(Pm2,3ST-M144D or Pd2,6ST)-mediated glycan modification. Whole embryo frozen sections from C57BL/6 mouse (E16) were incubated with either STs and CMP-SiaNAz-biotin 
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before staining with Alexa Fluor 594-streptavidin and imaged using fluorescence microscopy. In contrast to the higher background of the traditional two-step strategy using azide-bearing unnatural sugars followed by CuAAC-conjugation of biotin, Pd2,6ST-mediated one-step tissue glycan labeling showed much better contrast ( Supplementary Fig. 5 ). Interestingly, compared to samples without enzyme-treatments, tissue slides treated with STs showed robust fluorescence with distinct labeling patterns ( Fig. 3 , and Supplementary Fig. 6 , 7). The outer skin and the salivary gland region exhibited intensive signals afforded by labeling with both enzymes. Interestingly, Pd2,6ST-labeling generated significantly higher signals than Pm2,3ST-M144D-labeling in bone structures, including the sections of leg, rib, spine, and skull. When tissue sections were digested first with PNGase F to remove N-glycans before incubating with either STs, CMP-SiaNAz-biotin, and Alexa Fluor 594-streptavidin, Alexa Fluor 594-associated fluorescence was still detectable in most organs, strongly suggesting that other glycoconjugates (e.g., O-glycans) are also labeled ( Supplementary Fig. 7 ).
Probing IAV-HA-glycan interactions via live cell-based array.
As another application of chemoenzymatic cell-surface glycan modification, we probed how changes to live host-cell glycosylation patterns impact IAV infection. The attachment of the HA of IAV to the sialylated glycans of host epithelium is the first step in the viral entry cycle 17 . Glycan microarrays have been heavily employed to identify sialylated glycoepitopes that act as host receptors for IAV and to uncover the Sia binding-preferences of different HAs or whole viruses [28] [29] [30] [31] [32] [33] . It has been found that human IAVs prefer NeuAcα2-6-linked to Gal (human-type), which is abundantly expressed on epithelial cells of the human airway. By contrast, avian IAVs prefer NeuAcα2-3-Gal (aviantype) and bind poorly to the human upper airway epithelium [34] [35] [36] [37] . Despite the rich information gleaned from glycan microarray-based analyses, our understanding of HA-glycan interactions is incomplete without elucidating its physiological relevance. The solid-phase based glycan arrays do not capture the entire potential diversity of glycans present on the cell surface. As revealed by the lectin staining of lung tissues from different donors, cell-surface glycosylation patterns vary from individual to individual, exhibiting fluctuations in α2-3-or α2-6-linked sialylation, α1-3-fucosylation, and sLe X expression (Fig. 4a , and Supplementary Fig. 8 ). The variation of glycan expression in a person's respiratory tract may possibly account for differential susceptibility to influenza infection. We hypothesize that creating specific glycan epitopes that were previously identified by microarray-based binding assays directly on the live cell surface may serve as a quick way to dissect their specific contributions in a more native environment. Currently, only two influenza A subtypes circulate within humans: namely H1N1 and H3N2 31 . Using Lec2 cells and a combination of the four enzymes described above, we assembled a small cell-based glycan array (Fig. 4b) . We incubated the HA of influenza A/HongKong/1/1968 (HK68, H3N2) with this array and assessed its binding preference. As expected, HA of HK68 exhibited strong preference for NeuAcα2-6-linked to Gal. Surprisingly, it also exhibited significant binding with sLe X created by 1,3FT and 2,3 ST on the cell surface (Fig. 4c) .
Studying IAV infection in glycan-modified host cells. To evaluate if the interaction with sLe X on the host-cell surface plays any role in the viral infection, we adopted a live cell-based infection assay, in which we in situ edited the glycocalyx of Madin-Darby canine kidney (MDCK) cells, a well-established cell line for studying IAV, using the aforementioned glycosyltransferases. Cultures of the glycocalyx-modified cells, untreated cells, or cells treated with nucleotide sugars only were infected with serial dilutions of IAV in 96-well plates. This assay provides a direct approach to evaluate the impact of Sia and Fuc that are attached to the cell surface with distinct linkages on the susceptibility of host cells to IAV infection, enabling correlating glycosylation patterns with host-cell killing.
As found previously, both NeuAcα2-6-Gal and NeuAcα2-3-Gal are present on the surface of MDCK cells 38 . However, the expression level of NeuAcα2-6-Gal is low 39 . Using Pd2,6ST, additional NeuAcα2-6-Gal epitopes can be created by adding NeuAc to the terminal and internal Gal residues of the LacNAc repeats ( Fig. 5a and Supplementary Fig. 9B ). This is confirmed by the increase in the SNA staining, which reached a plateau wheñ 250 μM CMP-NeuAc was used ( Supplementary Fig. 10A ). Likewise, using Hp1,3 FT-mediated in situ Fuc modification, sLe X epitopes can be readily created as confirmed by the anticutaneous lymphocyte-associated antigen (anti-CLA) immunostaining (Fig. 5b) . To futher characterize the newly created glycan epitopes on the cell surface, we performed MALDI-TOF analysis of N-linked glycans of the Sia-edited and Fuc-edited cells. As shown in Supplementary Fig. 11 , the appearence of a tetraantennary N-glycan with four sialic acids added to the peripheral galactose was clearly identified in Sia-edited cells, but was not detectable in untreated MDCK cells. In addition, the peak intensity corresonding to sialylated bi-antennary epitopes (designated with asterisk in Supplementary Figs. 11B and 11C ) also increased significantly. Likewise, the newly created bi-antennary, tri-antennary, and tetra-antennary sLe X epitopes, as well as a tetra-antennary Le X , were found in Fuc-edited cells.
Naturally occurring H3N2 strains, HK68, A/Aichi/2/1968 (Aichi68) and A/Perth/16/2009 (Perth09), and an H1N1 strain, A/Solomon Islands/3/2006 (SI06), as well as two laboratoryderived H1N1 strains, A/WSN/33 (WSN) and A/Puerto Rico/8/ 1934 (PR8), were used in this infection assay. We first subjected MDCK cells to Pd2,6ST-mediated or FT-mediated modification to increase cell-surface NeuAcα2-6-Gal epitopes or create new sLe X epitopes, respectively. Next, we incubated the modified cells or cells treated with nucleotide sugars only with serial dilutions of IAV. Two days later, the host-cell viability was analyzed.
As expected, increasing NeuAcα2-6-Gal epitopes enhanced IAV-dependent cell killing for all strains tested, especially at high viral titers (Fig. 5) . As shown in Supplementary Fig. 9B , the higher the concentration of CMP-NeuAc that was used to install NeuAc onto the cell surface, the more severe the HK68-induced killing became. It was clearly observed that the killing reached a plateau at 10 −5 and 10 -4 viral dilutions when~250 μM CMPNeuAc was used, which is consistent with the maximum amounts of NeuAc residues that can be installed on MDCK cells. In the control experiment, treating cells with the donor substrate CMPNeuAc but without Pd2,6ST only had a minor impact on viral infection (Figs. 5c-i) . Interestingly, the newly added sLe X epitopes on the host-cell surface also augmented influenza-induced cell death (Figs. 5d-i) . At 10 -1 viral dilution, 50 ± 4% (±, the standard deviation of six biological replicates), 39 ± 2%, 53 ± 6% of the sLe x decorated cells remained viable upon incubating with Aichi68, Perth09 or SI06 (H1N1), respectively. By contrast, 68 ± 2%, 48 ± 3%, 78 ± 6% of the unmodified cells were viable upon infection by these viral strains. More pronounced effects induced by the sLe x addition were observed upon infection with HK68, WSN, or PR8; at 10 -3 viral dilution, only 73 ± 6%, 40 ± 1%, 41 ± 1% of the infected cells that were modified by sLe x remained viable, respectively, whereas 89 ± 3%, 62 ± 1%, 92 ± 2% of the unmodified cells were viable following infection by these viral strains. The fucosyltransferease-mediated sLe X creation also induced dosedependent host-cell killing upon IAV infection. As shown in Supplementary Fig. 12 for the infection with WSN, at a viral dilution of 10 −3 -10 −5 , the maximum killing was achieved wheñ 100 μM GDP-Fuc was used ( Supplementary Fig. 12B ), which is consistent with the maximum quantities of sLe X epitopes that can be created on MDCK cells (Supplementary Fig. 12A ).
MDCK cells modified by unnatural Sia and Fuc analogs were also evaluated in this infection assay using HK68. As shown in Fig. 5j , although C-9-and N-acetyl-Az modified Sia α2-6-linked to Gal exhibited similar activities as the natural ones to promote the influenza virus infection, α2-6-linked SiaNAl and SiaNPoc installed via the same fashion showed reduced activities ( Fig. 5j and Supplementary Fig. 13 ). Finally, all Fuc analogs examined were found to share similar functions at 10 −3 virus titer. However, at 10 −4 virus titer, the alkyne-bearing fucose analog, FucAl, seemed to enhance host-cell infection by HK68 (Fig. 5k, l) .
Profiling the structural constraints of HA for glycan binding. Then, the impacts of different HA structures on the binding of host-cell-surface glycan were profiled via chemoenzymatic glycan modification. H3N2 IAV have circulated in humans since 1968, but antigenic drift of HA continues to be a driving force that enables the virus to escape prior immunity. Since the major antigenic sites of the HA overlap with the receptorbinding site (RBS), the virus constantly evolves to effectively adapt to host immune responses without compromising its virulence [40] [41] [42] . The RBS consists of the 130-loop, 150-loop, 190-helix, and 220-loop (Wilson et al., 1981) 43 . While the 130-loop, 150-loop, and 190-helix are relatively conserved among HA subtypes, a higher genetic diversity has been detected in the 220-loop, which reflects also some differences in residues responsible for receptor specificity in the different subtypes (e.g., H1N1 vs. H3N2) 29, 30 .
To examine if sequence variation within the HA-RBS confers H3N2 influenza viruses any advantage to infect host cells harboring NeuAcα2-6-Gal epitopes or sLe X epitopes, we further assessed the wild-type HK68 virus and three laboratory-derived 220-loop mutants that can potentially escape from preexisting immunity, although exhibiting weaker binding toward the NeuAcα2-6-Gal receptor 41 . HK68-MTA (G225M/L226T/ S228A), HK68-LSS (G225L/L226S), and HK68-QAS (G225Q/ L226A) share a very similar HA backbone conformation, but their binding affinity for NeuAcα2-6-Gal decreases following the order of HK68-MTA > HK68-LSS > HK68-QAS 41 . All three mutants were found to have WT-like virus replication fitness in unmodified MDCK cells presumably due to the low level of α2-6-linked Sia expressed in this cell line.
To evaluate viral infection in MDCK cells harboring elevated NeuAcα2-6-Gal epitopes or sLe X epitopes, we treated the glycanmodified cells with WT HK68 or the three mutants. Consistent with previous observations 41 , all four strains exhibited similar HK68-MTA, whereas HK68-LSS and HK68-QAS exhibited decreased capability to infect sLe X -decorated host cells (Figs. 6e-i) .
Compared with HK68, HK68-MTA was found to possess better preference for sLe X harboring cells, especially at low viral titers (Fig. 6i) . In order to probe the molecular basis for this observation, apo structures of HK68-WT HA (PDB 4FNK) 44 and HK68-MTA HA (PDB 5VTX) 41 were aligned with the crystal structure of A/ canine/Colorado/17864/06 (H3 subtype) 45 HA in complex with sLe X using the RBS (residues 117-265 of HA1) 46 . As previously described 41 , a minor shift of 220-loop backbone of 0.8 Å was observed in HK68-MTA HA. Our alignment revealed that this shift likely enabled the formation of an H-bond between the C4 hydroxyl of Fuc and Nε1 of W222 (Fig. 6j) 49 .
In this study, we discovered that bacteria-derived Pm2,3ST-M144D, Pd2,6ST, and Hm1,2FT can be exploited for cell-surface glycan labeling and modification. As demonstrated previously and also here, these enzymes were easily prepared in multimilligram quantities in E. coli as His-tagged recombinant proteins. Among these three enzymes, Pm2,3ST-M144D and Pd2,6ST were found to tolerate a CMP-Sia donor functionalized with biotin or Cy3, enabling cell-surface acceptor glycans to be tagged with these probes for enrichment or visualization. Applying Pm2,3ST-M144D and Pd2,6ST-mediated chemoenzymatic glycan modification to label whole embryo frozen sections from C57BL/6 mice (E16), we found that the salivary gland expressed high levels of acceptor glycans of both enzymes. Sia was first isolated from bovine submaxillary mucin by Blix in 1936 50 . Thus, it is not surprising that salivary gland expressed high levels of sialyltransferase acceptors. Interestingly, in the developing bones Pd2,6ST-labeling yielded much higher signals than Pm2,3ST-M144D-labeling. Although Pm2,3ST-M144D can only label the terminal Gal, Pd2,6ST is capable of labeling galactoses of internal LacNAc units 22 . The distinct labeling pattern observed here suggests that abundant polyLacNAc glycans are present in bones and in cartilage. This observation is consistent with a previous report that revealed that polyLacNAc were predominantly found in N-glycans of undifferentiated human bone marrow mesenchymal stem cells 51 .
Combined together with our previously discovered H. pylori 1,3FT, Pm2,3ST-M144D and Pd2,6ST were used to create a diverse array of sialylated and fucosylated glycan epitopes on the cell surface. By using MDCK cells modified via this enzymemediated glycan modification to probe the infection of wild-type HK68 and its HA mutants, we confirmed that the ability of an IAV to induce host-cell death is positively correlated to the SiaNAcα2-6-Gal binding affinity of the viral HA. Furthermore, this correlation is dose dependent-only at high levels of cell-surface NeuAcα2-6-Gal can this correlation be observed. Unexpectedly, besides NeuAcα2-6-Gal receptors, several naturally occurring H1N1 and H3N2 strains also recognized sLe X epitopes on the host cells, to facilitate their infection. As is the case for the newly created NeuAcα2-6-Gal epitopes, increasing the quantity of sLe X on the cell surface exacerbates the severity of IAV infection in a dose-dependent manner.
HA is the major surface antigen that evolves at an exceptionally high rate. Variation in the HA-RBS through antigenic drift has produced changes in receptor binding that begins to blur the definition of human-type receptor specificity 42, [52] [53] [54] . Our investigation uncovered that several H3N2 and H1N1 strains, including Aichi68 (H3N2), WSN (H1N1), and PR8 (H1N1), exhibit preference for high sLe X -bearing cells over high SiaNAcα2-6-Gal-bearing cells especially at low viral titers (Fig. 5) . At low virus dilutions, these strains induced significantly higher levels of cell death in sLe X -harboring MDCK cells than in SiaNAcα2-6-Gal-harboring counterparts. These observations suggest that such strains may selectively infect human populations with high sLe X -expression in their respiratory tracts, such as patients with cystic fibrosis and patients suffering from airway inflammation 55 . It has been documented that several avian influenza virus strains exhibit strong affinities for sLe X -type receptors 36, 37, 56 . Therefore, it is likely that human populations with high sLe X -expression in their respiratory tracts are susceptible to these viruses as well.
Our studies strongly suggested that binding specificity and strength to HA are not only encoded in the structure of individual glycans, but also are determined by the density of these epitopes on the cell surface, which is contributed by repeating unit copies that are found in a single glycan or its neighboring structures. This context-dependent molecular recognition underscores the importance of tools that empower the investigation of glycan functions within a more native environment such as the cell surface. The chemoenzymatic glycan modification technique described here should serve as a valuable tool for accomplishing this goal. Currently, we are applying this technique to explore the impact of changes to cell-surface glycosylation patterns on the infection of other types of human viruses.
Methods
Enzyme activity assay for donor and acceptor substrates. The activity of purified enzymes was tested by TLC and LC-MS. All reactions were carried out at 37°C in 40 μL of 50 mM Tris-HCl (pH 7.5) containing 10 mM MgSO 4 . 5 mM N-acetyllactosamine (LacNAc) was used as the acceptor substrate for all enzymes, and 5 mM CMP-NeuAc or GDP-Fucose as the donor. For Hp1,3FT, Pd2,6ST, and Pm2,3ST-M144D, the enzymes were added at a concentration of 0.15 μg/μL, and the reaction time was 30 min. Hm1,2FT was used at 0.3 μg/μL, and the reaction time was 4 h. To further investigate the acceptor specificity of the enzymes, we performed sequential enzymatic reactions, by adding another enzyme and the required donor substrate after completing the current reaction. Lewis X (Le X )was produced by fucosylating LacNAc with Hp1,3FT as described above, and sialyl-Lewis X (sLe X ) was produced by adding 5 mM CMP-NeuAc and 0.15 μg/μL Pm2,3ST to the reaction. Fucα1-2-(NeuAcα2-6)-Galβ1-4GlcNAc or Lewis Y (Le Y ) was generated by sequentially adding Hm1,2FT and Pd2,6ST (or Hp1,3FT) reactions, respectively. The donor tolerance tests were performed under the same conditions above using unnatural nucleotide sugar analogs (GDP-FucAz and GDP-FucAl). For TLC analysis, isopropanol: H 2 O: NH 4 OH (8:3:2) was used as the development solvent, the nucleotide sugar was visualized under a 365 nm ultraviolet lamp, while LacNAc and the products were visualized by staining with 10% sulfuric acid in ethanol. For LC-MS analysis, 100 μL of ethanol was added to the reaction mixture and centrifuged at 13,000 × g for 2 min. The supernatant was then analyzed by LC-MS under positive mode (for fucosyltransferases-catalyzed reactions) or negative mode (for sialyltransferasescatalyzed reactions). 
